FDA Approval Insights: Dostarlimab in dMMR Advanced Endometrial Cancer

Season 8, Episode 36,   Apr 13, 2023, 06:00 PM

Headliner
Share
Subscribe

Dr Gilbert discusses the FDA approval of dostarlimab in patients with endometrial cancer, key efficacy data from the GARNET trial, and how this agent bolsters the endometrial cancer treatment paradigm.

Share
Subscribe
Next
Desai Discusses the Significance of a Supportive, Foundational Fellowship Experience
Top episodes
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air
Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
by OncLive® On Air